Health Care [ 2/12 ] | Pharmaceuticals [ 6/73 ]
NASDAQ | Common Stock
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States.
The company's product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum.
It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts.
The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma.
Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 12, 25 | 0.02 Increased by +105.41% | -0.09 Increased by +122.22% |
| May 12, 25 | -0.10 Increased by +77.27% | -0.14 Increased by +26.47% |
| Feb 26, 25 | -0.20 Increased by +62.02% | -0.24 Increased by +16.82% |
| Nov 7, 24 | -0.49 Increased by +9.26% | -0.37 Decreased by -32.43% |
| Aug 14, 24 | -0.37 Decreased by -54.17% | -0.42 Increased by +11.90% |
| May 13, 24 | -0.44 Decreased by -193.33% | -0.40 Decreased by -10.00% |
| Feb 29, 24 | -0.53 Decreased by -278.57% | -0.53 |
| Nov 9, 23 | -0.54 Decreased by -1.90 K% | -0.36 Decreased by -50.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 12.70 M Increased by +145.35% | 204.00 K Increased by +101.19% | Increased by +1.61% Increased by +100.48% |
| Mar 31, 25 | 3.44 M Decreased by -10.12% | -9.74 M Increased by +52.08% | Decreased by -283.28% Increased by +46.69% |
| Dec 31, 24 | 344.00 K Decreased by -82.70% | -16.20 M Increased by +34.18% | Decreased by -4.71 K% Decreased by -280.40% |
| Sep 30, 24 | -1.78 M Decreased by -161.06% | -22.86 M Increased by +7.83% | Increased by +1.28 K% Increased by +250.96% |
| Jun 30, 24 | 5.18 M Increased by +2.74 K% | -17.19 M Decreased by -56.38% | Decreased by -331.97% Increased by +94.50% |
| Mar 31, 24 | 3.83 M Increased by +10.24 K% | -20.33 M Decreased by -208.56% | Decreased by -531.39% Increased by +97.02% |
| Dec 31, 23 | 1.99 M Increased by +2.82 K% | -24.61 M Decreased by -335.57% | Decreased by -1.24 K% Increased by +85.10% |
| Sep 30, 23 | 2.92 M Decreased by -64.94% | -24.80 M Decreased by -29.98 K% | Decreased by -850.26% Decreased by -85.32 K% |